{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:23:19Z","timestamp":1791663799521,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015694","name":"Florence Savings Bank Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell&apos;Istruzione dell&apos;Universita e della Ricerca","doi-asserted-by":"publisher","award":["CUP B83C22003920001"],"award-info":[{"award-number":["CUP B83C22003920001"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neuropharm.2026.110857","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:23:54Z","timestamp":1769559834000},"page":"110857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The potent and selective adenosine A2AR antagonists P400 and P625 protect against symptoms in autoimmune experimental encephalomyelitis by attenuating neuroinflammation and demyelination"],"prefix":"10.1016","volume":"288","author":[{"given":"M.","family":"Morozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Borgonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7961-0536","authenticated-orcid":false,"given":"C.","family":"Sasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8236-0849","authenticated-orcid":false,"given":"G.","family":"Videtta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2255-9250","authenticated-orcid":false,"given":"S.","family":"Calenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-928X","authenticated-orcid":false,"given":"D.","family":"Catarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-9427","authenticated-orcid":false,"given":"F.","family":"Varano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9296-6819","authenticated-orcid":false,"given":"V.","family":"Colotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-9844","authenticated-orcid":false,"given":"N.","family":"Galeotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.110857_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imlet.2018.04.006","article-title":"Adenosine signaling and the immune system: when a lot could be too much","volume":"205","author":"Antonioli","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.neuropharm.2026.110857_bib2","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1007\/s12035-023-03236-8","article-title":"Posttranscriptional regulation of gene expression participates in the myelin restoration in mouse models of multiple sclerosis: antisense modulation of HuR and HuD ELAV RNA binding protein","volume":"60","author":"Borgonetti","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105431","article-title":"Combined inhibition of histone deacetylases and BET family proteins as epigenetic therapy for nerve injury-induced neuropathic pain","volume":"165","author":"Borgonetti","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2026.110857_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154670","article-title":"Zingiberene, a non-zinc-binding class I HDAC inhibitor: a novel strategy for the management of neuropathic pain","volume":"111","author":"Borgonetti","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.neuropharm.2026.110857_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.neuropharm.2026.110857_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets--what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2026.110857_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104490","article-title":"The adenosine A2A receptor antagonist SCH5 8261 reduces macrophage\/microglia activation and protects against experimental autoimmune encephalomyelitis in mice","volume":"129","author":"Chen","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2026.110857_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104490","article-title":"The adenosine A2A receptor antagonist SCH5 8261 reduces macrophage\/microglia activation and protects against experimental autoimmune encephalomyelitis in mice","volume":"129","author":"Chen","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2026.110857_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2026.110857_bib10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib11","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2026.110857_bib12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cmdc.200600193","article-title":"Highlights on the development of A(2A) adenosine receptor agonists and antagonists","volume":"2","author":"Cristalli","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuropharm.2026.110857_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib14","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00348.2003","article-title":"Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction","volume":"286","author":"Day","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/13524585241311212","article-title":"Neurofilament heavy chain in secondary progressive multiple sclerosis","volume":"31","author":"De Angelis","year":"2025","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuropharm.2026.110857_bib16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjp.0701119","article-title":"Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261","volume":"121","author":"Dionisotti","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2009.05.010","article-title":"Adenosine A2A receptor deficiency exacerbates white matter lesions and cognitive deficits induced by chronic cerebral hypoperfusion in mice","volume":"285","author":"Duan","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2026.110857_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1474-4422(14)70231-5","article-title":"Treatment of progressive multiple sclerosis: what works, what does not, and what is needed","volume":"14","author":"Feinstein","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neuropharm.2005.09.005","article-title":"Blockade of intracellular calcium release induces an antidepressant-like effect in the mouse forced swimming test","volume":"50","author":"Galeotti","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110857_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.irn.2023.08.002","article-title":"Adenosine A2A receptor and glia","volume":"170","author":"Gao","year":"2023","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.tips.2005.08.004","article-title":"Adenosine receptor signaling in the brain immune system","volume":"26","author":"Hask\u00f3","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2026.110857_bib23","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"10.1016\/j.neuropharm.2026.110857_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.neuropharm.2026.110857_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0512-z","article-title":"Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation","volume":"13","author":"Ingwersen","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.110857_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102512","article-title":"Clinical outcome measures in multiple sclerosis: a review","volume":"19","author":"Inojosa","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neuropharm.2026.110857_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-013-0195-3","article-title":"Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models","volume":"22","author":"Khan","year":"2014","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuropharm.2026.110857_bib28","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41582-021-00556-y","article-title":"Apparent changes in the epidemiology and severity of multiple sclerosis","volume":"17","author":"Koch-Henriksen","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4155\/tde.11.149","article-title":"Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective","volume":"3","author":"Landis","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.neuropharm.2026.110857_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103932","article-title":"Multiple sclerosis incidence: a systematic review of change over time by geographical region","volume":"63","author":"Lane","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neuropharm.2026.110857_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.athoracsur.2009.06.032","article-title":"The role of adenosine A2A receptor signaling in bronchiolitis obliterans","volume":"88","author":"Lau","year":"2009","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.neuropharm.2026.110857_bib32","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/cns.13266","article-title":"Heterogeneity of microglia and their differential roles in white matter pathology","volume":"25","author":"Lee","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2026.110857_bib33","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd2358","article-title":"Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary","volume":"7","author":"Lopez-Diego","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2026.110857_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-9-233","article-title":"Pain in experimental autoimmune encephalitis: a comparative study between different mouse models","volume":"9","author":"Lu","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.110857_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/bph.12955","article-title":"Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP","author":"McGrath","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib36","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.4049\/jimmunol.1200545","article-title":"A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis","volume":"188","author":"Mills","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2005.05.032","article-title":"Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease","volume":"129","author":"Odashima","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2026.110857_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nn.2341","article-title":"Adenosine A(2A) receptor mediates microglial process retraction","volume":"12","author":"Orr","year":"2009","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.110857_bib39","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","article-title":"Microglia states and nomenclature: a field at its crossroads","volume":"110","author":"Paolicelli","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2026.110857_bib40","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.neuropharm.2026.110857_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neuropharm.2015.11.007","article-title":"Purinergic signalling in brain ischemia","volume":"104","author":"Pedata","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110857_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00402","article-title":"Adenosine A2A receptor signaling in the immunopathogenesis of experimental autoimmune encephalomyelitis","volume":"9","author":"Rajasundaram","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib43","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/jcbfm.2013.85","article-title":"Adenosine A2A receptors in secondary progressive multiple sclerosis: a [(11)C]TMSX brain PET study","volume":"33","author":"Rissanen","year":"2013","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2017.06.005","article-title":"Silencing of the RNA-binding protein HuR attenuates hyperalgesia and motor disability in experimental autoimmune encephalomyelitis","volume":"123","author":"Sanna","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110857_bib45","doi-asserted-by":"crossref","first-page":"231.e1","DOI":"10.1016\/j.ejpain.2010.07.010","article-title":"Characterisation of sensory abnormalities observed in an animal model of multiple sclerosis: a behavioural and pharmacological study","volume":"15","author":"Thibault","year":"2011","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2026.110857_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/298326","article-title":"Neuropathic pain in animal models of nervous system autoimmune diseases","author":"Tian","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.neuropharm.2026.110857_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13080161","article-title":"Piperazine- and piperidine-containing Thiazolo[5,4- d]pyrimidine derivatives as new potent and selective adenosine A2A receptor inverse agonists","volume":"13","author":"Varano","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuropharm.2026.110857_bib48","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1021\/acs.jmedchem.6b01068","article-title":"Design, synthesis, and pharmacological characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine derivatives: new highly potent A2A adenosine receptor inverse agonists with antinociceptive activity","volume":"59","author":"Varano","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2026.110857_bib49","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/eji.201343314","article-title":"Multiple sclerosis lymphocytes upregulate A2A adenosine receptors that are antiinflammatory when stimulated","volume":"43","author":"Vincenzi","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuropharm.2014.06.029","article-title":"Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism","volume":"86","author":"Wang","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110857_bib51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuropharm.2014.06.029","article-title":"Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism","volume":"86","author":"Wang","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110857_bib52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev-physiol-022516-034406","article-title":"Microglia in physiology and disease","volume":"79","author":"Wolf","year":"2017","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib53","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1084\/jem.20132477","article-title":"Differential roles of microglia and monocytes in the inflamed central nervous system","volume":"211","author":"Yamasaki","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuropharm.2026.110857_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1471-4159.2012.07807.x","article-title":"Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis","volume":"123","author":"Yao","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2026.110857_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-022-02415-z","article-title":"Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis","volume":"19","author":"Zheng","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.110857_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-022-02415-z","article-title":"Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis","volume":"19","author":"Zheng","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.110857_bib57","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"Optimizing treatment success in multiple sclerosis","volume":"263","author":"Ziemssen","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2026.110857_bib58","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1476-5381.1996.tb15296.x","article-title":"Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes","volume":"117","author":"Zocchi","year":"1996","journal-title":"Br. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:33:41Z","timestamp":1773992021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":58,"alternative-id":["S0028390826000304"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110857","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potent and selective adenosine A2AR antagonists P400 and P625 protect against symptoms in autoimmune experimental encephalomyelitis by attenuating neuroinflammation and demyelination","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110857"}}